A handheld optical coherence tomography (OCT) device could soon be helping clinicians to visualize and map the hidden spread of non-melanoma skin cancer (NMSC) under the skin. That's according to UK-based medical equipment firm Michelson Diagnostics, which has just secured an additional £1.7 million in venture capital funding to expand its clinical trials program and support the commercialization of its VivoSight product.
NMSC is the most common cancer in the US today -- current estimates put the number of new cases annually at around 3.5 million. In the UK alone there are an estimated 100,000 new cases of NMSC annually.
Michelson Diagnostics has established multiple clinical trials in several countries to assess the efficacy of its OCT technique. The company says that several hundred patients have been scanned to date, and that it will be expanding its trials to new sites in UK and USA in 2011.
Full story from Optics.org